| abstract |
Compounds of formula (I), in which R1 represents an aryl or heteroaryl group optionally substituted by one or more substituents selected from halogen, optionally substituted linear or branched lower alkyl, cycloalkyl, hydroxy, optionally substituted linear or branched lower alkoxy, -SH, optionally substituted linear or branched lower alkylthio, cano, -NR'R', -CO2R'; -R2 represents a group selected from -CO(CH2)nR3, -CO(CH2)nN(R4)R3, - COO(CH2)nR3 and -(CH2)nR3; in which n is 0, 1 or 2; R3 represents a group selected from: a) an optionally substituted monocyclic or polycyclic heteroaryl or aryl group or b) a lower, linear or branched alkyl or cycloalkyl group, which is optionally substituted; and -R4 represents a hydrogen atom or optionally substituted linear or branched lower alkyl group; they are useful for treating a pathological disorder or disease likely to be improved by antagonism of the adenosine A1 receptor. |